ACTIVE BIOTECH AB FOURTH QUARTER IN BRIEF
- Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis (
December 1 ) Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod (December 5 )Active Biotech announces outcome of the Company’s rights issue (December 6 )- Preclinical data of tasquinimod presented at ASH (
December 14 ) Active Biotech provides update on the scheduled clinical program for 2024 (December 22 )
OTHER SIGNIFICANT EVENTS JAN –
Active Biotech confirmed positive clinical safety profile of laquinimod eye drops (January 30 )- Safety and preliminary efficacy of naptumomab in combination with durvalumab presented at AACR 2023 (
April 19 ) - Positive interim data from the ongoing study of tasquinimod in heavily pre-treated patients with relapsed and refractory multiple myeloma presented at ASCO 2023 (
May 26 ) - Positive safety and tolerability in clinical phase I study and preclinical ocular biodistribution data supporting the further development of laquinimod eye drops for inflammatory eye diseases were established (
May 30 ) - New preclinical data regarding tasquinimod’s anti-fibrotic effects in myelofibrosis were presented at EHA 2023 (
June 10 ) - Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (
July 31 ) - Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (
September 11 ) - Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech’s website (
September 13 )
FINANCIAL SUMMARY
| SEK M | Oct-Dec | Jan-Dec | ||
| 2023 2022 | 2023 2022 | |||
| Net sales | - | - | - | - |
| Operating profit/loss | -12.8 | -15.2 | -46.5 | -57.9 |
| Profit/loss after tax | -12.5 | -15.0 | -45.8 | -58.4 |
| Earnings per share (SEK) | -0.04 | -0.06 | -0.17 | -0.25 |
| Cash and cash equivalents (at close of period) | 36.2 | 41.8 | ||
The report is also available at www.activebiotech.com.
This information was provided to the media, through the agency of the contact persons set out below, for publication on
© Modular Finance, source
